• Please log in or register to access this feature.

Original Articles

You have full text access to this OnlineOpen article

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

  1. Huiling Yang1,
  2. Christopher E. Westland1,
  3. William E. Delaney IV1,*,
  4. Elizabeth J. Heathcote2,
  5. Victoria Ho1,
  6. John Fry1,
  7. Carol Brosgart1,
  8. Craig S. Gibbs1,
  9. Michael D. Miller1,
  10. Shelly Xiong1

Article first published online: 30 DEC 2003

DOI: 10.1053/jhep.2002.34740

Issue

Hepatology

Hepatology

Volume 36, Issue 2, pages 464–473, August 2002

Additional Information

How to Cite

Yang, H., Westland, C. E., Delaney, W. E., Heathcote, E. J., Ho, V., Fry, J., Brosgart, C., Gibbs, C. S., Miller, M. D. and Xiong, S. (2002), Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology, 36: 464–473. doi: 10.1053/jhep.2002.34740

Author Information

  1. 1

    Gilead Sciences Inc., Foster City, CA

  2. 2

    Toronto Western Hospital, Toronto, Ontario, Canada

*Gilead Sciences Inc., 333 Lakeside Dr., Foster City, CA 94404. fax: 650-522-5890.

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003
  3. Manuscript Accepted: 16 MAY 2002
  4. Manuscript Received: 24 JAN 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (233K)

References

  • 1
    Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis [see comments]. Ann Intern Med 1993; 119:312–323.MEDLINE
  • 2
    Niederau C, Heintges T, Lange S, Goldmann G, Niederau C, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:1422–1427.MEDLINE
  • 3
    Dienstag J, Perrillo R, Schiff E, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:1657–1661.MEDLINE
  • 4
    Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25:241–244.MEDLINE
    Direct Link:
  • 5
    Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527–1532.MEDLINE
    Direct Link:
  • 6
    Chang TT, Lai CL, Liaw YF, Guan R, Lim SG, Lee CM, Ng KY, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years [abstract]. Antiviral Ther 2000; 5(Suppl 1):44.
  • 7
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847–851.MEDLINE
    Direct Link:
  • 8
    Liaw Y-F, Chien R-N, Yeh C-T, Tsai S-L, Chu C-M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567–572.MEDLINE
    Direct Link:
  • 9
    Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis b virus after long-term lamivudine therapy. Clin Infect Dis 2001; 33:403–405.MEDLINE
  • 10
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [see comments]. Lancet 1997; 349:20–22.MEDLINE
  • 11
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27:1670–1677.MEDLINE
    Direct Link:
  • 12
    Paik YH, Chung HY, Ryu WS, Lee KS, Lee JS, Kim JH, Lee CK, et al. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. J Hepatol 2001; 35:92–98.MEDLINE
  • 13
    Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32:1078–1088.MEDLINE
    Direct Link:
  • 14
    Fu L, Liu SH, Cheng YC. Sensitivity of L-(−)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999; 57:1351–1359.MEDLINE
  • 15
    Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107:449–455.MEDLINE
  • 16
    Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, Manns M, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (−)-β-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-β-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45:2495–2501.MEDLINE
  • 17
    Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation of therapy. Hepatology 1998; 27:1711–1716.MEDLINE
    Direct Link:
  • 18
    Delaney WE IV, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antiviral Chem Chemother 2001; 12:1–35.
  • 19
    De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986; 323:464–467.MEDLINE
  • 20
    Heijtink RA, De Wilde GA, Kruining J, Berk L, Balzarini J, De Clercq E, Holy A, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993; 21:141–153.MEDLINE
  • 21
    Nicoll AJ, Colledge DL, Toole JJ, Angus PW, Smallwood RA, Locarnini SA. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob Agents Chemother 1998; 42:3130–3135.MEDLINE
  • 22
    Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000; 32:139–146.MEDLINE
    Direct Link:
  • 23
    Cullen JM, Li DH, Brown C, Eisenberg EJ, Cundy KC, Wolfe J, Toole J, et al. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 2001; 45:2740–2745.MEDLINE
  • 24
    Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepatitis 1999; 6:387–395.
    Direct Link:
  • 25
    Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129–134.MEDLINE
    Direct Link:
  • 26
    Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs CS, Lamy P, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68:1912–1914.MEDLINE
  • 27
    Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, et al. Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718–723.MEDLINE
  • 28
    Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751–757.MEDLINE
    Direct Link:
  • 29
    Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000; 31:219–224.MEDLINE
    Direct Link:
  • 30
    Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro [see comments]. Hepatology 1998; 28:1669–1673.MEDLINE
    Direct Link:
  • 31
    Delaney WE IV, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45:1705–1713.MEDLINE
  • 32
    Sambrook J, Fritsch EF, Maniatis T. Analysis and cloning of eukaryotic genomic DNA. In: FordN, NolanC, FergusonM, editors. Molecular Cloning. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989: 9.1–9.62.
  • 33
    Gunther S, von Breunig F, Santantonio T, Jung MC, Gaeta GB, Fischer L, Sterneck M, et al. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. J Hepatol 1999; 30:749–754.MEDLINE
  • 34
    Seigneres B, Pichoud C, Ahmed SS, Hantz O, Trepo C, Zoulim F. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B [in process citation]. J Infect Dis 2000; 181:1221–1233.MEDLINE
  • 35
    de Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998; 29:669–675.MEDLINE
  • 36
    Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, Buchan S, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46:107–113.MEDLINE
  • 37
    Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7:113–117.MEDLINE
    Direct Link:
  • 38
    Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171:1411–1419.MEDLINE
  • 39
    Cherrington JM, Mulato AS, Fuller MD, Chen MS. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob Agents Chemother 1996; 40:2212–2216.MEDLINE
  • 40
    Mulato AS, Lamy PD, Miller MD, Li WX, Anton KE, Hellmann NS, Cherrington JM. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob Agents Chemother 1998; 42:1620–1628.MEDLINE
  • 41
    Miller MD, Margot NA, Lamy PD, Fuller MD, Anton KE, Mulato AS, Cherrington JM. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J AIDS 2001; 27:450–458.
  • 42
    Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial [see comments]. JAMA 1999; 282:2305–2312.MEDLINE
  • 43
    Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75:4771–4779.MEDLINE
  • 44
    Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37:15908–15917.MEDLINE
  • 45
    Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999; 4:35–43.MEDLINE
  • 46
    Meyer PR, Matsuura SE, Schinazi RF, So AG, Scott WA. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother 2000; 44:3465–3472.MEDLINE
  • 47
    Urban S, Fischer KP, Tyrrell DL. Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism. Proc Natl Acad Sci U S A 2001; 98:4984–4989.MEDLINE
  • 48
    Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antiviral Ther 2001; 6:115–126.
  • 49
    Luscombe C, Pedersen J, Bowden S, Locarnini S. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy. Liver 1994; 14:182–192.MEDLINE
  • 50
    Nicoll AJ, Angus PW, Chou ST, Luscombe CA, Smallwood RA, Locarnini SA. Demonstration of duck hepatitis B virus in bile duct epithelial cells: implications for pathogenesis and persistent infection. Hepatology 1997; 25:463–469.MEDLINE
    Direct Link:
  • 51
    Fu L, Cheng YC. Characterization of novel human hepatoma cell lines with stable Hepatitis b virus secretion for evaluating new compounds against Lamivudine- and Penciclovir-resistant virus. Antimicrob Agents Chemother 2000; 44:3402–3407.MEDLINE
Get PDF (233K)